The global neurovascular intervention devices market is expected to witness significant growth over the forecast period. The growth can be attributed to factors such as an increase in the target patient base, technological advancements, improving medical reimbursement in mature economies and expanding healthcare infrastructure. However, factors including lack of skilled neurosurgeons and expensive research and development may pose a challenge to industry growth.
Neurovascular intervention is a technique wherein any disease or damage is treated without the need for surgery, usually in regions which pose a high risk or a high chance of fatalities such as the spine, the brain or the neck.
Neurovascular intervention devices market can be segmented by technology, product, and geography. Geographical segmentation classifies four viable regions, namely North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa. A considerable targeted market is in the North American region including the U.S. accounting for over 60% of the revenue, followed by the Europe. Asia Pacific is also expected to showcase a healthy growth over the forecast period owing to large population base and relatively weak healthcare infrastructure in some parts. Rising interest in the field of neurosurgery and availability of cheap interventional neurology devices has further driven regional growth. The market is fragmented by technology into embolization & coiling, supporting techniques, carotid angioplasty & stenting, and neuro thrombectomy (mechanical removal of thrombus, usually from intracranial arteries).
Product based segmentation classifies the industry into cerebral angioplasty (balloon angioplasty) & stenting systems, aneurysm coiling and embolization devices, support devices, and neuro thrombectomy devices. Technological innovations in the fields of stenting and balloon angioplasty have led to a substantial growth in these two product segments but mostly in the mature markets of Europe, the US and Japan. Companies operating in this industry adopt geographic expansion and product development strategies to expand and strengthen their business. Global players in the neurovascular devices industry undertake acquisitions, partnerships & collaborations to develop and strengthen their businesses. However, companies in the developed countries which are already into medical devices manufacturing face challenges owing to rapid commercialization in the developing countries like India, Malaysia and China, which pose a potential for high demand and can keep production costs low.
Key industry participants include Stryker, Johnson & Johnson, Abbot Laboratories, Terumo Corporation, Penumbra, Medtronic, W. L. Gore & Associates, Johnson & Johnson, Microport Scientific Corporation. Though a lot of companies have consolidated with an aim to achieve competency, this industry is a much fragmented owing to the core competency in the product lines offered by various top players. This leads to varying market shares in the product segment when compared from one company to another. However, the leading companies such as Stryker Corporation, Medtronic, Terumo, Penumbra and Johnson & Johnson together enjoy a fair stand in the market with close to 85% share in the global neurovascular industry.
Regulatory policies governing the medical devices companies often create a barrier to growth as safety and health concerns are critical. Developing countries in the Asia-Pacific region are also actively investing in the neurovascular devices market, though not to the extent of actually posing a threat to the established companies. The cost-effectiveness of these regions in production and innovation of neurovascular related devices is creating a challenge for the major players with significant capital investments in R&D and production projects.
Increasing development in emerging markets across the globe especially India and Africa, are identified with a potential to gain business. These regions though currently facing fundamental health issues; however, with growing medical infrastructure and investment there exists a reasonable chance that the demand for neurovascular devices and procedures will rise.